A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms.
NCT00623870
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
116
Enrollment
INDUSTRY
Sponsor class
Conditions
Hematologic Neoplasms
Interventions
DRUG:
RO5045337
Sponsor
Hoffmann-La Roche